Ensysce Biosciences Stock Forum

$Ensysce Biosciences(ENSC.US)$
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed...

$Ensysce Biosciences(ENSC.US)$ we going to a dollar

$Ensysce Biosciences(ENSC.US)$
NEWS
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Ensysce Biosciences has renewed its collaboration with Quotient Sciences to advance the clinical development of its overdose protection platform, PF614-MPAR. This innovative opioid product, designed to prevent overdose by shutting off opioid release when too many pills are ingested, is undergoing a Phase 1b study to evaluate its efficacy a...

$Ensysce Biosciences(ENSC.US)$ keep going...

$Ensysce Biosciences(ENSC.US)$ creeping.
.90 promised??

$Ensysce Biosciences(ENSC.US)$ BUY!

$Ensysce Biosciences(ENSC.US)$ Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)
Benzinga· 4 mins ago

In an unprecedented move towards improving opioid safety, Ensysce Biosciences Inc. recently announced a successful meeting with the U.S. Food and Drug Administration (FDA) regarding its next-generation opioid, PF614-MPAR. This pivotal development not only marks a significant milestone for Ensysce but could also have far-reaching implications for the entirety of the opioid industry. $Ensysce Biosciences(ENSC.US)$
...

$Ensysce Biosciences(ENSC.US)$ Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program
Benzinga· 2 mins ago
The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of severe pain. The FDA provided helpful feedback and advice on non-clinical studies that are required for eventual new drug application (NDA) submission and approval. The guidance will aid in streamlining the development plans for this innovative drug candi...